Every 8-K that STERIS plc (STE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow STE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full STE filings page.
STERIS plc held its 2026 Annual General Meeting of Shareholders on July 31, 2026. There were 97,457,680 ordinary shares outstanding and entitled to vote, and holders of 89,909,204 shares, or 92.25%, were present in person or by proxy, constituting a quorum. Effective upon completion of the meeting, the size of the Board of Directors was set at nine members.
Shareholders cast votes for nine director nominees, including Dr. Esther M. Alegria, Pierre Boulud, Daniel A. Carestio, Cynthia L. Feldmann, Christopher S. Holland, Paul E. Martin, Dr. Nirav R. Shah, Louis A. Shapiro and Dr. Mohsen M. Sohi, with each nominee receiving tens of millions of votes in favor. The results also detail votes for and against several additional management proposals, with broker non-votes where applicable.
STERIS plc reports that Director Pierre Boulud, whose election and the expansion of the Board from nine to ten members were previously disclosed, has received his initial committee assignments. Effective July 31, 2026, he was appointed to the Board’s Audit Committee and its Compliance and Technology Committee.
The company notes that no other changes were made to the matters previously reported regarding the Board’s composition or Mr. Boulud’s role.
STERIS plc reported fiscal 2027 first-quarter results and outlined a new chemistries consolidation plan. Revenue rose 7% to $1.5 billion, with constant currency organic growth of 6%. Net income attributable to shareholders was $200.1 million and diluted EPS was $2.04, up from $1.79. Adjusted EPS increased to $2.59 from $2.34.
Healthcare revenue grew 8% to $1.05 billion, Applied Sterilization Technologies 6% to $297.6 million, and Life Sciences 9% to $146.7 million, with operating income higher in all three segments. Operating cash flow was $367.1 million and free cash flow $279.6 million, lower than the prior year mainly because working capital contributed less, partly offset by higher net income.
The company announced a targeted restructuring linked to a new formulated chemistries Center of Excellence in North Carolina. STERIS expects total pre-tax restructuring charges of $55–$70 million, including $40–$50 million of cash costs and $15–$20 million of non-cash charges, with completion anticipated during fiscal 2030; these will be excluded from adjusted earnings. The company reaffirmed its fiscal 2027 outlook for 7–8% reported revenue growth and adjusted EPS of $11.10–$11.30, while increasing planned capital expenditures to about $450 million and lowering expected free cash flow to approximately $800 million.
STERIS plc reported strong results for fiscal 2026 and raised its outlook. Revenue from continuing operations grew 9% to $5.94 billion, while constant currency organic revenue increased 7%. As reported diluted EPS from continuing operations rose to $7.93, and adjusted EPS increased to $10.17.
Growth was broad-based: Healthcare revenue reached $4.21 billion, AST $1.14 billion, and Life Sciences $588.8 million. Net income from continuing operations was $782.3 million, and free cash flow improved to $982.9 million on operating cash flow of $1.34 billion.
For fiscal 2027, STERIS expects reported revenue to grow 7–8% and constant currency organic revenue 6–7%. Adjusted EPS is projected between $11.10 and $11.30, up 9–11% from fiscal 2026. The Board also authorized a new $1 billion share repurchase program, and capital expenditures of about $375 million will include a new sterility assurance plant in Mentor, Ohio.
STERIS plc reported changes to its Board of Directors. Long-serving director Richard C. Breeden will retire and not stand for reelection at the 2026 Annual General Meeting, with the company noting his decision is not due to any disagreement over operations, policies or practices.
The Board increased its size from nine to ten members and appointed Pierre Boulud, CEO of bioMérieux, as a director effective May 5, 2026. He brings experience in in vitro diagnostics, biopharma and strategy roles. Boulud will receive a prorated fee of $76,989 for the 2025-26 Board term, paid in career restricted stock units under STERIS’s Non-Employee Director Compensation Program.
STERIS plc amended its Transition Agreement with former Chief Financial Officer Michael J. Tokich to keep him on as a part-time senior financial advisor from April 1, 2026 through March 31, 2027, called the Extended Advisor Period.
During this time, his annual base salary will be reduced to $60,000, he may receive a discretionary cash bonus approved by the Compensation and Organization Development Committee, and he will no longer be eligible for the Company’s health, dental, life insurance, vacation, disability or other employee benefit plans. All other terms of the original Agreement remain in effect during the Extended Advisor Period.
STERIS plc filed a current report stating that it has released financial results for its fiscal 2026 third quarter, covering the quarter ended December 31, 2025. The company announced these results through a press release dated February 4, 2026, which is attached as Exhibit 99.1 and furnished, rather than filed, with regulators.
STERIS plc furnished an 8-K to announce it issued a press release with financial results for the quarter ended September 30, 2025, which is its fiscal 2026 second quarter. The press release is attached as Exhibit 99.1.
The information under Item 2.02, including Exhibit 99.1, is being furnished to the SEC, not deemed “filed” under Section 18 of the Exchange Act, and is not incorporated by reference into Securities Act filings.